Creoptix — a Malvern Panalytical brand
THE WAVE OF THE FUTURE IN KINETICS.
Experience a new level of performance and flexibility in drug discovery.
By bringing together modern label-free technology, application development know-how and sophisticated software, Creoptix offers a unique optical biosensor tool for binding kinetics. Engineered around our proprietary Grating-Coupled Interferometry (GCI) technology, the Creoptix WAVEsystem delivers high-quality kinetic data across a broader range of samples than traditional SPR equipment.
Following integration in January 2022, Creoptix is a Malvern Panalytical brand.
About Malvern Panalytical:
We draw on the power of our analytical instruments and services to make the invisible visible and the impossible possible.
Through the chemical, physical and structural analysis of materials, our high precision analytical systems and top-notch services support our customers in creating a better world. Malvern Panalytical. We’re BIG on small™
Antibody Screening Made Easy With The New Creoptix Ligand Screening Wizard
How to quantify active protein? With the Calibration Free Concentration Analysis from Creoptix
No-Clog Microfluidics: A Smooth Ride Through the Creoptix® WAVEsystem
Challenges and opportunities in Drug Screening
Why Domainex uses Creoptix® WAVEsystem for biophysical screening
All in one: No-clog microfluidics, high sensitivity and flexible data evaluation
Recording of kinetic information at high resolution and sensitity
High sensitivity and low bulk effect with Creoptix® Grating-Coupled Interferometry
Biophysical screening workflow with Creoptix® WAVEdelta and GCI technology
WAVEchip®: Microfluidics redefined
waveRAPID®: Screening of 80 known kinase inhibitors
Real-time interaction analysis with Creoptix® WAVEsystem
Introduction to waveRAPID®
Dynamics & Trends in Molecular Interaction Analysis
Accelerating HIT expansion with waveRAPID® I Dr. Trevor Askwith (Domainex)
How to save time with WAVEchips | Microfluidics redefined
Creoptix WAVE: Explore the system's components
Fragment screening with WAVEsystem | Novartis and leadXpro
Sensitivity with Grating-Coupled Interferometry (GCI) vs. Surface Plasmon Resonance (SPR)